BWX Technologies (NYSE:BWXT) (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.
Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment. The company operates facilities in the United States and Canada to manufacture molybdenum-99 and other critical isotopes, ensuring a secure supply chain for global healthcare providers. Its commercial portfolio also includes pressure vessels, nuclear steam generators and material science services that serve conventional and advanced reactor designs.
Formed in 2015 following the acquisition of Babcock & Wilcox’s commercial nuclear operations by Brookfield Asset Management, BWXT Technologies became an independent, publicly traded company later that year. Since its spin-off, BWXT has expanded its footprint through strategic investments in research and development, as well as partnerships aimed at advancing SMR deployment in North America and overseas.
Headquartered in Lynchburg, Virginia, BWXT employs a workforce across multiple sites in the United States, Canada and the United Kingdom. Under the leadership of President and Chief Executive Officer Brett A. Taylor, the company continues to pursue innovation in nuclear technology, focusing on safety, quality and sustainability to meet the diverse needs of government, industrial and healthcare customers worldwide.
